News & Events

University of Illinois Cancer Center member Takeshi Shimamura, PhD, studies how some cancers can become resistant to treatment, including a stubborn form of lung cancer that learns to resist some FDA-approved drugs. His latest study in the journal Cancer Letters introduces a drug designed to block two key proteins that help cancer survive and spread, even after other treatments stop working. The new molecule binds to two proteins that work together to spread cancerous cells.

Click here to read more about the study and listen to a story summary in UIC Today.

Shimamura, the study corresponding author, is part of the Cancer Center Cancer Biology Research Program and Associate Professor in the Department of Surgery at the University of Illinois College of Medicine at UIC. Other UIC study authors include fellow Cancer Center member Ian Papautsky, PhD, part of the Cancer Center Translational Oncology Research Program, and study first author Ines Pulido, PhD, who is part of Shimamura’s lab and a Cancer Center trainee.